Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer’s disease using multiple e-pharmacophore modeling and molecular dynamics

References

• Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005). Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRX, 2, 554–571.10.1602/neurorx.2.4.554
   PubMedGoogle Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., … Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28, 235–242.10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Blay, J. Y., & von Mehren, M. (2011). Nilotinib: A novel, selective tyrosine kinase inhibitor. Seminars in Oncology, 38(Suppl. 1), S3–S9.10.1053/j.seminoncol.2011.01.016
   PubMedGoogle Scholar
• Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & Dementia, 3, 186–191.10.1016/j.jalz.2007.04.381
   PubMed Web of Science ®Google Scholar
• Cancino, G. I., Perez de Arce, K., Castro, P. U., Toledo, E. M., von Bernhardi, R., & Alvarez, A. R. (2011). c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice. Neurobiology of Aging, 32, 1249–1261.10.1016/j.neurobiolaging.2009.07.007
   PubMed Web of Science ®Google Scholar
• Chen, Z., Tian, G., Wang, Z., Jiang, H., Shen, J., & Zhu, W. (2010). Multiple pharmacophore models combined with molecular docking: A reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity. Journal of Chemical Information and Modeling, 50, 615–625.10.1021/ci9004173
   PubMed Web of Science ®Google Scholar
• Cohen, A. D., Ikonomovic, M. D., Abrahamson, E. E., Paljug, W. R., DeKosky, S. T., Lefterov, I. M., & Klunk, W. E. (2009). Anti-amyloid effects of small molecule abeta-binding agents in PS1/APP mice. Letters in Drug Design & Discovery, 6, 437–444.10.2174/157018009789057526
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., & Manley, P. W. (2007). Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallographica Section D Biological Crystallography, 63, 80–93.10.1107/S0907444906047287
   PubMed Web of Science ®Google Scholar
• De Strooper, B., Vassar, R., & Golde, T. (2010). The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nature Reviews Neurology, 6, 99–107.10.1038/nrneurol.2009.218
   PubMed Web of Science ®Google Scholar
• Derkinderen, P., Scales, T. M., Hanger, D. P., Leung, K. Y., Byers, H. L., Ward, M. A., & Anderton, B. H. (2005). Tyrosine 394 is phosphorylated in Alzheimer’s paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. [Research Support, Non-U.S. Gov’t]. Journal of Neuroscience, 25, 6584–6593.10.1523/JNEUROSCI.1487-05.2005
   PubMed Web of Science ®Google Scholar
• Dineen, T. A., Weiss, M. M., Williamson, T., Acton, P., Babu-Khan, S., Bartberger, M. D., & Zhong, W. (2012). Design and synthesis of potent, orally efficacious hydroxyethylamine derived beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. Journal of Medicinal Chemistry, 55, 9025–9044.10.1021/jm300118s
   PubMed Web of Science ®Google Scholar
• Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., & Friesner, R. A. (2006). PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design, 20, 647–671.10.1007/s10822-006-9087-6
   PubMed Web of Science ®Google Scholar
• Dixon, S. L., Smondyrev, A. M., & Rao, S. N. (2006). PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chemical Biology Drug Design, 67, 370–372.10.1111/jpp.2006.67.issue-5
   PubMed Web of Science ®Google Scholar
• Eisenberg, D., & Jucker, M. (2012). The amyloid state of proteins in human diseases. Cell, 148, 1188–1203.10.1016/j.cell.2012.02.022
   PubMed Web of Science ®Google Scholar
• Fargo, K., & Bleiler, L. (2014). 2014 Alzheimer’s disease facts and figures. Alzheimers Dement, 10, e47–92.
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., & Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47, 1739–1749.10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medical Chemistry, 49, 6177–6196.
   PubMed Web of Science ®Google Scholar
• Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10, 449–461.10.1517/17460441.2015.1032936
   PubMed Web of Science ®Google Scholar
• Ghosh, A. K., Gemma, S., & Tang, J. (2008). β-Secretase as a therapeutic target for Alzheimer’s disease. Neurotherapeutics, 5, 399–408.10.1016/j.nurt.2008.05.007
   PubMed Web of Science ®Google Scholar
• Godschalk, F., Genheden, S., Soderhjelm, P., & Ryde, U. (2013). Comparison of MM/GBSA calculations based on explicit and implicit solvent simulations. Physical Chemistry Chemical Physics, 15, 7731–7739.10.1039/c3cp00116d
   PubMed Web of Science ®Google Scholar
• Greenwood, J. R., Calkins, D., Sullivan, A. P., & Shelley, J. C. (2010). Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. Journal of Computer-Aided Molecular Design, 24, 591–604.10.1007/s10822-010-9349-1
   PubMed Web of Science ®Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47, 1750–1759.10.1021/jm030644s
   PubMed Web of Science ®Google Scholar
• Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends in Pharmacological Sciences, 12, 383–388.
   PubMed Web of Science ®Google Scholar
• Horio, T., Hamasaki, T., Inoue, T., Wakayama, T., Itou, S., Naito, H., & Niwa, T. (2007). Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorganic & Medicinal Chemistry Letters, 17, 2712–2717.10.1016/j.bmcl.2007.03.002
   PubMed Web of Science ®Google Scholar
• Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. Journal of Computational Chemistry, 32, 866–877.10.1002/jcc.v32.5
   PubMed Web of Science ®Google Scholar
• Huang, N., Shoichet, B. K., & Irwin, J. J. (2006). Benchmarking sets for molecular docking. Journal of Medicinal Chemistry, 49, 6789–6801.10.1021/jm0608356
   PubMed Web of Science ®Google Scholar
• Imam, S. Z., Zhou, Q., Yamamoto, A., Valente, A. J., Ali, S. F., Bains, M., … Li, S. (2011). Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: Implications for Parkinson’s disease. Journal of Neuroscience, 31, 157–163.10.1523/JNEUROSCI.1833-10.2011
   PubMed Web of Science ®Google Scholar
• Iqbal, K., Liu, F., Gong, C. X., & Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. Current Alzheimer Research, 7, 656–664.10.2174/156720510793611592
   PubMed Web of Science ®Google Scholar
• John, S., Thangapandian, S., Sakkiah, S., & Lee, K. W. (2011). Potent bace-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinformatics, 12(Suppl. 1), S28.10.1186/1471-2105-12-S1-S28
   PubMedGoogle Scholar
• Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O’Brien, S., Wassmann, B., & Ottmann, O. G. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL. New England Journal of Medicine, 354, 2542–2551.10.1056/NEJMoa055104
   PubMed Web of Science ®Google Scholar
• Karran, E., Mercken, M., & De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nature Reviews Drug Discovery, 10, 698–712.10.1038/nrd3505
   PubMed Web of Science ®Google Scholar
• Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2014). The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease. Scientific Reports, 4, 4874-1–4874-8.
   Web of Science ®Google Scholar
• Landau, M., Sawaya, M. R., Faull, K. F., Laganowsky, A., Jiang, L., Sievers, S. A., & Eisenberg, D. (2011). Towards a pharmacophore for amyloid. PLoS Biology, 9, e1001080.10.1371/journal.pbio.1001080
   PubMed Web of Science ®Google Scholar
• Lane, R. F., Shineman, D. W., Steele, J. W., Lee, L. B., & Fillit, H. M. (2012). Beyond amyloid: The future of therapeutics for Alzheimer’s disease. Advances in Pharmacology, 64, 213–271.10.1016/B978-0-12-394816-8.00007-6
   PubMedGoogle Scholar
• Loving, K., Salam, N. K., & Sherman, W. (2009). Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. Journal of Computer-Aided Molecular Design, 23, 541–554.10.1007/s10822-009-9268-1
   PubMed Web of Science ®Google Scholar
• Lyne, P. D., Lamb, M. L., & Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. Journal of Medicinal Chemistry, 49, 4805–4808.10.1021/jm060522a
   PubMed Web of Science ®Google Scholar
• Mahul-Mellier, A. L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., … Lashuel, H. A. (2014). c-Abl phosphorylates alpha-synuclein and regulates its degradation: Implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson’s disease. Human Molecular Genetics, 23, 2858–2879.10.1093/hmg/ddt674
   PubMed Web of Science ®Google Scholar
• Mucs, D., Bryce, R. A., & Bonnet, P. (2011). Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors. Journal of Computer-Aided Molecular Design, 25, 569–581.10.1007/s10822-011-9442-0
   PubMed Web of Science ®Google Scholar
• O’Brien, R. J., & Wong, P. C. (2011). Amyloid precursor protein processing and Alzheimer’s disease. Annual Review of Neuroscience, 34, 185–204.10.1146/annurev-neuro-061010-113613
   PubMed Web of Science ®Google Scholar
• Okram, B., Nagle, A., Adrián, F. J., Lee, C., Ren, P., Wang, X., & Gray, N. S. (2006). A general strategy for creating “inactive-conformation” Abl inhibitors. Chemistry & Biology, 13, 779–786.10.1016/j.chembiol.2006.05.015
   PubMed Web of Science ®Google Scholar
• Palakurti, R., Sriram, D., Yogeeswari, P., & Vadrevu, R. (2013). Multiple e-pharmacophore modeling combined with high-throughput virtual screening and docking to identify potential inhibitors of β-Secretase(BACE1). Molecular Informatics, 32, 385–398.10.1002/minf.201200169
   PubMed Web of Science ®Google Scholar
• Pardridge, W. M. (2009). Alzheimer’s disease drug development and the problem of the blood-brain barrier. Alzheimer’s & Dementia, 5, 427–432.10.1016/j.jalz.2009.06.003
   PubMed Web of Science ®Google Scholar
• Poornima, C. S., & Dean, P. M. (1995). Hydration in drug design. 1. Multiple hydrogen-bonding features of water molecules in mediating protein-ligand interactions. Journal of Computer-Aided Molecular Design, 9, 500–512.10.1007/BF00124321
   PubMed Web of Science ®Google Scholar
• Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S., Smykla, R., & Lee, F. Y. (2008). Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112, 1005–1012.10.1182/blood-2008-02-140665
   PubMed Web of Science ®Google Scholar
• Reddy, E. P., & Aggarwal, A. K. (2012). The ins and outs of Bcr-Abl inhibition. Genes Cancer, 3, 447–454.10.1177/1947601912462126
   PubMedGoogle Scholar
• Salam, N. K., Nuti, R., & Sherman, W. (2009). Novel method for generating structure-based pharmacophores using energetic analysis. Journal of Chemical Information and Modeling, 49, 2356–2368.10.1021/ci900212v
   PubMed Web of Science ®Google Scholar
• Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27, 221–234.10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Schlatterer, S. D., Tremblay, M. A., Acker, C. M., & Davies, P. (2011). Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. Journal of Alzheimer’s Disease, 25, 119–133.
   PubMed Web of Science ®Google Scholar
• Seeliger, M. A., Ranjitkar, P., Kasap, C., Shan, Y., Shaw, D. E., Shah, N. P., … Maly, D. J. (2009). Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Research, 69, 2384–2392.10.1158/0008-5472.CAN-08-3953
   PubMed Web of Science ®Google Scholar
• Senior, K. (2003). Gleevec does not cross blood-brain barrier. The Lancet Oncology, 4, 198.10.1016/S1470-2045(03)01050-7
   PubMed Web of Science ®Google Scholar
• Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., & Sherman, W. (2009). Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. Journal of Chemical Theory and Computation, 6, 1509–1519.
   Web of Science ®Google Scholar
• Stierand, K., & Rarey, M. (2010). Drawing the PDB: Protein-ligand complexes in two dimensions. ACS Medicinal Chemistry Letters, 1, 540–545.10.1021/ml100164p
   PubMed Web of Science ®Google Scholar
• Wang, J., Hou, T., & Xu, X. (2006). Recent advances in free energy calculations with a combination of molecular mechanics and continuum models. Current Computer-Aided Drug Design, 2, 95–103.
   Web of Science ®Google Scholar
• Watts, K. S., Dalal, P., Murphy, R. B., Sherman, W., Friesner, R. A., & Shelley, J. C. (2010). ConfGen: A conformational search method for efficient generation of bioactive conformers. Journal of Chemical Information and Modeling, 50, 534–546.10.1021/ci100015j
   PubMed Web of Science ®Google Scholar
• Weisberg, E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W., Ray, A., … Griffin, J. D. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7, 129–141.10.1016/j.ccr.2005.01.007
   PubMed Web of Science ®Google Scholar
• Xiong, Y. Z., & Chen, P. Y. (2008). ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase. Journal of Molecular Modeling, 14, 1083–1086.
   PubMed Web of Science ®Google Scholar
• Zhang, H. Y. (2005). One-compound-multiple-targets strategy to combat Alzheimer’s disease. FEBS Letters, 579, 5260–5264.10.1016/j.febslet.2005.09.006
   PubMed Web of Science ®Google Scholar
• Zhu, Q., Chen, J., Wu, X., Jin, X., & Ruan, B. (2014). Repurposing of kinase inhibitors to target c-Abl as potential therapeutics for Alzheimer’s disease. Journal of Pharmaceutical Innovation, 9, 331–340.10.1007/s12247-014-9202-5
   Web of Science ®Google Scholar